Stojilković S S, Dufau M L, Catt K J
Endocrinology. 1987 Jul;121(1):384-94. doi: 10.1210/endo-121-1-384.
The potent opiate radioligands [3H]etorphine, [3H]ethylketocyclazocine (EKC), and [3H]naloxone, bound specifically and saturably to a single class of membrane-binding sites in rat neurointermediate lobe (NIL), with Kd values of 3.7, 24, and 51 nM, respectively. In the hypothalamus (Ht), [3H]etorphine bound to specific and saturable sites with a Kd of 2.9 nM. Binding-inhibition studies with [3H]etorphine and unlabeled etorphine-HCl as well as [3H]EKC and unlabeled EKC, revealed high and low affinity binding sites in rat Ht and NIL as well as in the neural lobe of the bovine pituitary gland. [3H]naloxone also bound specifically to two classes of sites in Ht membranes, but to only a single class of low affinity sites in NIL membranes. Specific binding represented 80-90% of total [3H]etorphine binding, about 75% of total [3H]EKC binding, and 45-55% of total [3H]naloxone binding at 22 C in NIL and Ht, respectively. Relative binding potencies derived from Ki values for binding-inhibition studies of [3H]etorphine with opioid peptides and opiates were: NIL, etorphine-HCl greater than dynorphin A greater than naloxone-HCl greater than dynorphin-(1-9) greater than beta-endorphin much greater than alpha-neoendorphin approximately (Leu5)enkephalin approximately DAGO (Tyr-D-Ala-Gly-NMe-Phe-Gly-ol); Ht, etorphine HCl greater than naloxone-HCl greater than beta-endorphin greater than dynorphin A much greater than DAGO greater than morphiceptin much greater than (Leu5)enkephalin. Specific [3H]etorphine binding was also demonstrable after preincubation of NIL membranes with DAGO and (Leu5)enkephalin and after preincubation of Ht membranes with morphiceptin and (Leu5)enkephalin; such binding could be displaced by nonradioactive dynorphin A. In addition, [3H]etorphine binding to bovine neural lobe was displaceable by naloxone-HCl, with an ED50 of 43 nM. Specific ligands for sigma-opiate receptors, such as (+)SKF 10,047 (N-allylnorcyclazocine), phencyclidine (PCP), and (-)cyclazocine, displaced specifically bound [3H]etorphine and [3H]EKC from NIL membranes only at high (micromolar) concentrations. However, specific [3H]PCP sites were of higher affinity in NIL and Ht membranes, with similar Kd values of 102 and 190 nM respectively, and different concentrations (0.15 and 1.32 pmol/mg protein, respectively). These data have revealed several differences in the opiate-binding properties of rat Ht and NIL membranes.(ABSTRACT TRUNCATED AT 400 WORDS)
强效阿片类放射性配体[3H]埃托啡、[3H]乙基酮环唑辛(EKC)和[3H]纳洛酮,特异性且可饱和地结合于大鼠神经中间叶(NIL)的一类膜结合位点,其解离常数(Kd)值分别为3.7、24和51 nM。在下丘脑(Ht)中,[3H]埃托啡以2.9 nM的Kd值结合于特异性且可饱和的位点。用[3H]埃托啡和未标记的盐酸埃托啡以及[3H]EKC和未标记的EKC进行的结合抑制研究表明,在大鼠Ht和NIL以及牛垂体神经叶中存在高亲和力和低亲和力结合位点。[3H]纳洛酮也特异性地结合于Ht膜中的两类位点,但仅结合于NIL膜中的一类低亲和力位点。在22℃时,特异性结合在NIL和Ht中分别占[3H]埃托啡总结合量的80 - 90%、[3H]EKC总结合量的约75%以及[3H]纳洛酮总结合量的45 - 55%。通过[3H]埃托啡与阿片肽及阿片类药物结合抑制研究的Ki值得出的相对结合亲和力为:NIL中,盐酸埃托啡>强啡肽A>盐酸纳洛酮>强啡肽 -(1 - 9)>β - 内啡肽>α - 新内啡肽≈亮氨酸脑啡肽≈DAGO(酪氨酰 - D - 丙氨酰 - 甘氨酰 - N - 甲基苯丙氨酰 - 甘氨醇);Ht中,盐酸埃托啡>盐酸纳洛酮>β - 内啡肽>强啡肽A>DAGO>吗啡肽>亮氨酸脑啡肽。在NIL膜与DAGO和亮氨酸脑啡肽预孵育以及Ht膜与吗啡肽和亮氨酸脑啡肽预孵育后,也可检测到特异性[3H]埃托啡结合;这种结合可被非放射性强啡肽A取代。此外,[3H]埃托啡与牛神经叶的结合可被盐酸纳洛酮取代,半数有效剂量(ED50)为43 nM。σ - 阿片受体的特异性配体,如(+)SKF 10,047(N - 烯丙基去甲环唑辛)、苯环己哌啶(PCP)和( - )环唑辛,仅在高(微摩尔)浓度下才能特异性地从NIL膜中取代结合的[3H]埃托啡和[3H]EKC。然而,特异性[3H]PCP位点在NIL和Ht膜中的亲和力更高,其Kd值分别为102和190 nM,浓度分别为0.